Concepedia

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial

Andrew X. Zhu, Joon Oh Park, Baek‐Yeol Ryoo, Chia-Jui Yen, Ronnie T. P. Poon, Davide Pastorelli, Jean-Frédéric Blanc, Hyun Cheol Chung, Ari David Baron, Túlio Pfiffer,

The Lancet Oncology · 2015 · 845 citations · 26 references

DOIFull text

Open access

Concepts

References

26

Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

Jacques Ferlay, Isabelle Soerjomataram, Rajesh Dikshit et al. · International Journal of Cancer · 2014 · 29K citations · Full text

, , +16

Sorafenib in Advanced Hepatocellular Carcinoma

Josep M. Llovet, Sergio Ricci, Vincenzo Mazzaferro et al. · New England Journal of Medicine · 2008 · 13K citations · Full text

, , +12

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

Ann‐Lii Cheng, Yoon‐Koo Kang, Zhendong Chen et al. · The Lancet Oncology · 2008 · 5.8K citations

, , +11

Sorafenib in Advanced Hepatocellular Carcinoma

재연 정 · 2008 · 5.6K citations

, , +12

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

Charles S. Fuchs, Jiří Tomášek, Filip Dumitru et al. · The Lancet · 2013 · 2.2K citations · Full text

, , +12